Literature DB >> 11420890

Disposition of amiodarone in rats after single and multiple intra-peritoneal doses.

T A Najjar1.   

Abstract

The pharmacokinetics of amiodarone was studied after single and multiple dosing in two groups of male Wistar and Albino rats. The first group (40 rats) received a single intraperitoneal (i.p.) dose of amiodarone (100 mg/kg) and 4 rats sacrificed 1, 2, 4, 6, 12, 18, 24, 36, 48 and 72 hours post dosing. The second group (42 rats) received amiodarone (50 mg/kg, i.p., daily) for 5 days a week for 5 weeks and 6 rats were sacrificed at 1, 2, 3, 4, 5, 6 and 8 weeks. Rats of both group were sampled for blood, heart, lung and fat and the concentrations of amiodarone in these samples were determined using. The elimination of amiodarone from plasma after single dose followed a biphasic pattern with a terminal half-life of 54.7 +/- 8.2 hours. The concentrations of amiodarone in the tissues were halved within 26.8, 34.9 and 37.45 hours in the heart, lung and fat, respectively. The average concentrations of amiodarone in plasma, heart, lung and fat after single dose were 1.24 micrograms/ml, 1.73 micrograms/mg, 7.61 micrograms/mg and 29.01 micrograms/mg, respectively. The concentration of amiodarone after multiple dosing were halved within 8.4, 5.5, 6.4 and 9.8 days, for the plasma, heart, lung and fat, respectively. The average concentrations of amiodarone in plasma, heart, lung and fat during multiple doses were 0.97 microgram/mg, 7.63 micrograms/mg and 65.01 micrograms/mg respectively. In conclusion, after multiple dosing, the elimination half-life of amiodarone and its fat contents were 3.7 and 2.8 times greater than that after single dosing. The excessive amount of amiodarone observed in fat tissues after multiple dosing is probably the reason for the prolonged elimination half-life. Based on the elimination half-lives data, the time to steady state is about two weeks and the drug should be withheld for less than a mont if a patient required discontinuation because of serious adverse effects.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11420890     DOI: 10.1007/BF03192314

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  17 in total

Review 1.  Clinical pharmacokinetics of amiodarone.

Authors:  C I Haffajee
Journal:  Clin Cardiol       Date:  1987-07       Impact factor: 2.882

Review 2.  Practical follow-up guidelines for patients treated with amiodarone.

Authors:  P J Podrid
Journal:  Clin Cardiol       Date:  1987-07       Impact factor: 2.882

3.  Serum concentrations of amiodarone during long term therapy. Relation to dose, efficacy and toxicity.

Authors:  M Stäubli; J Bircher; R L Galeazzi; H Remund; H Studer
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

4.  Plasma concentration time course and pharmacological effects of a standardized oral amiodarone dosing regimen in humans.

Authors:  F J Brennan; J F Brien; P W Armstrong
Journal:  Can J Cardiol       Date:  1991-04       Impact factor: 5.223

Review 5.  Clinical pharmacokinetics of amiodarone.

Authors:  R Latini; G Tognoni; R E Kates
Journal:  Clin Pharmacokinet       Date:  1984 Mar-Apr       Impact factor: 6.447

6.  Concentration response relationships of amiodarone and desethylamiodarone.

Authors:  S J Connolly; R N Gupta; D Hoffert; R S Roberts
Journal:  Am Heart J       Date:  1988-06       Impact factor: 4.749

7.  Incidence, predictability, and pathogenesis of amiodarone-induced thyrotoxicosis and hypothyroidism.

Authors:  M D Trip; W Wiersinga; T A Plomp
Journal:  Am J Med       Date:  1991-11       Impact factor: 4.965

8.  Two cases of amiodarone-induced thyrotoxicosis successfully treated with a short course of antithyroid drugs while amiodarone was continued.

Authors:  M D Trip; D R Düren; W M Wiersinga
Journal:  Br Heart J       Date:  1994-09

9.  Amiodarone pharmacokinetics. II. Disposition kinetics following subchronic administration in rats.

Authors:  S J Weir; C T Ueda
Journal:  Biopharm Drug Dispos       Date:  1987 Sep-Oct       Impact factor: 1.627

10.  Pharmacokinetics and body distribution of amiodarone and desethylamiodarone in rats after oral administration.

Authors:  T A Plomp; W M Wiersinga; J M Van Rossum; R A Maes
Journal:  In Vivo       Date:  1987 Sep-Oct       Impact factor: 2.155

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.